Population pharmacokinetics of exenatide
Open Access
- 21 September 2016
- journal article
- pharmacokinetics
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 83 (3), 517-526
- https://doi.org/10.1111/bcp.13135
Abstract
Aim The aim of the present analysis was to develop a core population pharmacokinetic model for the pharmacokinetic properties of immediate‐release (IR) exenatide, which can be used in subsequent analyses of novel sustained‐release formulations. Methods Data from eight clinical trials, evaluating a wide range of doses and different administration routes, were available for analysis. All modelling and simulations were conducted using the nonlinear mixed‐effect modelling program NONMEM. External model validation was performed using data from the phase III clinical trials programme through standard visual predictive checks. Results The pharmacokinetics of IR exenatide was described by a two‐compartment model, and the absorption of subcutaneous exenatide was described with a sequential zero‐order rate constant followed by a saturable nonlinear absorption process. Drug elimination was characterized by two parallel routes (linear and nonlinear), with significant relationships between renal function and the linear elimination route, and between body weight and volume of distribution. For a subject with normal renal function, the linear clearance was estimated to be 5.06 l hr−1. The nonlinear elimination was quantified with a Michaelis–Menten constant (Km) of 567 pg ml−1 and a maximum rate of metabolism (Vmax) of 1.6 μg h−1. For subcutaneous administration, 37% of the subcutaneous dose is absorbed via the zero‐order process, and the remaining 63% via the nonlinear pathway. Conclusions The present analysis provides a comprehensive population pharmacokinetic model for exenatide, expanding the elimination process to include both linear and nonlinear components, providing a suitable platform for a broad range of concentrations and patient conditions that can be leveraged in future modelling efforts of sustained‐release exenatide formulations.Keywords
This publication has 31 references indexed in Scilit:
- Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjectsBritish Journal of Clinical Pharmacology, 2013
- Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys, and HumansDrug Metabolism and Disposition, 2012
- Clinical relevance of anti‐exenatide antibodies: safety, efficacy and cross‐reactivity with long‐term treatmentDiabetes, Obesity and Metabolism, 2012
- Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 DiabetesDiabetes Technology & Therapeutics, 2011
- Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki RatsThe Journal of pharmacology and experimental therapeutics, 2010
- Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic modelsJournal of Pharmacokinetics and Pharmacodynamics, 2009
- Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetesAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Effect of renal impairment on the pharmacokinetics of exenatideBritish Journal of Clinical Pharmacology, 2007
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1Drug Development Research, 2001